Vesna Tesic1, Srdjan M Joksimovic1, Nidia Quillinan2, Kathiresan Krishnan3, Douglas F Covey4, Slobodan M Todorovic2, Vesna Jevtovic-Todorovic5. 1. Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 2. Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA; Neuroscience Graduate Program, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. 3. Department of Developmental Biology, Washington University School of Medicine, St Louis, MO, USA. 4. Department of Developmental Biology, Washington University School of Medicine, St Louis, MO, USA; Taylor Family Institute for Innovative Psychiatric Research, Washington University School of Medicine, St Louis, MO, USA. 5. Department of Anesthesiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: vesna.jevtovic-todorovic@ucdenver.edu.
Abstract
BACKGROUND: The most currently used general anaesthetics are potent potentiators of γ-aminobutyric acid A (GABAA) receptors and are invariably neurotoxic during the early stages of brain development in preclinical animal models. As causality between GABAA potentiation and anaesthetic-induced developmental neurotoxicity has not been established, the question remains whether GABAergic activity is crucial for promoting/enhancing neurotoxicity. Using the neurosteroid analogue, (3α,5α)-3-hydroxy-13,24-cyclo-18,21-dinorchol-22-en-24-ol (CDNC24), which potentiates recombinant GABAA receptors, we examined whether this potentiation is the driving force in inducing neurotoxicity during development. METHODS: The neurotoxic potential of CDNC24 was examined vis-à-vis propofol (2,6-diisopropylphenol) and alphaxalone (5α-pregnan-3α-ol-11,20-dione) at the peak of rat synaptogenesis. In addition to the morphological neurotoxicity studies of the subiculum and medial prefrontal cortex (mPFC), we assessed the extra-, pre-, and postsynaptic effects of these agents on GABAergic neurotransmission in acute subicular slices from rat pups. RESULTS: CDNC24, like alphaxalone and propofol, caused dose-dependent hypnosis in vivo, with a higher therapeutic index. CDNC24 and alphaxalone, unlike propofol, did not cause developmental neuroapoptosis in the subiculum and mPFC. Propofol potentiated post- and extrasynaptic GABAA currents as evidenced by increased spontaneous inhibitory postsynaptic current (sIPSC) decay time and prominent tonic currents, respectively. CDNC24 and alphaxalone had a similar postsynaptic effect, but also displayed a strong presynaptic effect as evidenced by decreased frequency of sIPSCs and induced moderate tonic currents. CONCLUSIONS: The lack of neurotoxicity of CDNC24 and alphaxalone may be at least partly related to suppression of presynaptic GABA release in the developing brain.
BACKGROUND: The most currently used general anaesthetics are potent potentiators of γ-aminobutyric acid A (GABAA) receptors and are invariably neurotoxic during the early stages of brain development in preclinical animal models. As causality between GABAA potentiation and anaesthetic-induced developmental neurotoxicity has not been established, the question remains whether GABAergic activity is crucial for promoting/enhancing neurotoxicity. Using the neurosteroid analogue, (3α,5α)-3-hydroxy-13,24-cyclo-18,21-dinorchol-22-en-24-ol (CDNC24), which potentiates recombinant GABAA receptors, we examined whether this potentiation is the driving force in inducing neurotoxicity during development. METHODS: The neurotoxic potential of CDNC24 was examined vis-à-vis propofol (2,6-diisopropylphenol) and alphaxalone (5α-pregnan-3α-ol-11,20-dione) at the peak of rat synaptogenesis. In addition to the morphological neurotoxicity studies of the subiculum and medial prefrontal cortex (mPFC), we assessed the extra-, pre-, and postsynaptic effects of these agents on GABAergic neurotransmission in acute subicular slices from rat pups. RESULTS: CDNC24, like alphaxalone and propofol, caused dose-dependent hypnosis in vivo, with a higher therapeutic index. CDNC24 and alphaxalone, unlike propofol, did not cause developmental neuroapoptosis in the subiculum and mPFC. Propofol potentiated post- and extrasynaptic GABAA currents as evidenced by increased spontaneous inhibitory postsynaptic current (sIPSC) decay time and prominent tonic currents, respectively. CDNC24 and alphaxalone had a similar postsynaptic effect, but also displayed a strong presynaptic effect as evidenced by decreased frequency of sIPSCs and induced moderate tonic currents. CONCLUSIONS: The lack of neurotoxicity of CDNC24 and alphaxalone may be at least partly related to suppression of presynaptic GABA release in the developing brain.
Authors: Ege T Kavalali; Chihye Chung; Mikhail Khvotchev; Jeremy Leitz; Elena Nosyreva; Jesica Raingo; Denise M O Ramirez Journal: Physiology (Bethesda) Date: 2011-02
Authors: Fang Liu; Shuo W Rainosek; Jessica L Frisch-Daiello; Tucker A Patterson; Merle G Paule; William Slikker; Cheng Wang; Xianlin Han Journal: Toxicol Sci Date: 2015-07-23 Impact factor: 4.849
Authors: Francesca M Manzella; Douglas F Covey; Vesna Jevtovic-Todorovic; Slobodan M Todorovic Journal: J Neuroendocrinol Date: 2022-01-10 Impact factor: 3.627
Authors: Quy L Tat; Srdjan M Joksimovic; Kathiresan Krishnan; Douglas F Covey; Slobodan M Todorovic; Vesna Jevtovic-Todorovic Journal: Cells Date: 2020-12-12 Impact factor: 6.600
Authors: Stefan Maksimovic; Nemanja Useinovic; Nidia Quillinan; Douglas F Covey; Slobodan M Todorovic; Vesna Jevtovic-Todorovic Journal: Int J Mol Sci Date: 2022-02-08 Impact factor: 5.923